Daxor Corp (DXR)
NASDAQ:DXR
Want to see DXR full AI Analyst Report?
DXR Stock Chart & Stats
$9.43
-$0.12(-1.54%)
At close: 4:00 PM EST
$9.43
-$0.12(-1.54%)
Day’s Range― - ―
52-Week Range$8.29 - $14.76
Previous CloseN/A
Volume734.00
Average Volume (3M)1.99K
Market Cap
N/A
Enterprise Value$51.91M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$112.00K
Price to Earnings (P/E)6.1
Beta0.66
Next Earnings
Aug 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.82
Shares Outstanding5,827,225
10 Day Avg. Volume865
30 Day Avg. Volume1,994
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.60
Price to Sales (P/S)146.07
P/FCF Ratio-121.66
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue345.61
Enterprise Value/Gross Profit-601.59
Enterprise Value/Ebitda5.44
Forecast
1Y Price Target
$22.50Price Target Upside138.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$11.90M
Bulls Say, Bears Say
Bulls Say
Clinical Validation And Customer AdoptionExtensive clinical validation backed by peer‑reviewed studies and tens of thousands of performed tests, together with new customer wins at multiple medical centers, supports broad clinical applicability and clinician confidence in the device.
Product Innovation And Workflow ImprovementThe handheld blood volume analyzer delivers lab‑grade precision with faster turnaround and substantially reduced blood requirements, improving portability and streamlining clinical workflow for office‑based testing.
Regulatory And Market AccessA planned CLIA waiver submission for moderate‑complexity testing could allow use in non‑CLIA labs and nontraditional care settings, expanding the addressable market and facilitating more physician office activations.
Bears Say
Investment Structure And ValuationThe company's designation as a specific investment fund structure has reduced visibility among traditional investors and may be suppressing its valuation despite operational progress.
Operating Losses From R&D And CommercializationOperating division losses driven by investments in research, development, and commercial capabilities for the next‑generation analyzer increase cash burn and place pressure on near‑term profitability.
Daxor News
DXR FAQ
What was Daxor Corp’s price range in the past 12 months?
Daxor Corp lowest stock price was $8.29 and its highest was $14.76 in the past 12 months.
What is Daxor Corp’s market cap?
Currently, no data Available
When is Daxor Corp’s upcoming earnings report date?
Daxor Corp’s upcoming earnings report date is Aug 20, 2026 which is in 76 days.
How were Daxor Corp’s earnings last quarter?
Daxor Corp released its earnings results on Mar 03, 2026. The company reported $1.885 earnings per share for the quarter, beating the consensus estimate of N/A by $1.885.
Is Daxor Corp overvalued?
According to Wall Street analysts Daxor Corp’s price is currently Undervalued.
Does Daxor Corp pay dividends?
Daxor Corp pays a Monthly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Daxor Corp dividends here
What is Daxor Corp’s EPS estimate?
Daxor Corp’s EPS estimate is -0.03.
How many shares outstanding does Daxor Corp have?
Daxor Corp has 5,827,225 shares outstanding.
What happened to Daxor Corp’s price movement after its last earnings report?
Daxor Corp reported an EPS of $1.885 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.879%.
Which hedge fund is a major shareholder of Daxor Corp?
Currently, no hedge funds are holding shares in DXR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daxor Corp
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
DXR Stock 12 Month Forecast
Average Price Target
$22.50
▲(138.60% Upside)
Technical Analysis
Ownership Overview
5.43% Insiders
0.84% Mutual Funds
5.10% Other Institutional Investors
87.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---